New Alzheimer's drug aims to ease symptoms and help caregivers

NCT ID NCT07633470

Recruiting now Symptom relief Sponsor: Alpha Cognition, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests the safety and tolerability of the drug Zunveyl in 150 adults aged 50 and older with mild to moderate Alzheimer's disease. Over 12 weeks, researchers will monitor side effects and whether the drug helps reduce neuropsychiatric symptoms like agitation or mood changes, and lessens distress for caregivers. The goal is to see if Zunveyl can improve daily life for patients and their families.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Alzheimer's Disease Research Center
RECRUITING

Albany, New York, 12208, United States
CCM Clinical Research Group, LLC
RECRUITING

Miami, Florida, 33133, United States
Essential Concepts Research Solutions (ECRS)
RECRUITING

Palos Hills, Illinois, 60465, United States
Progressive Medical Research
RECRUITING

Port Orange, Florida, 32127, United States
Tekton Research Saint Louis Psychiatry
RECRUITING

St Louis, Missouri, 63128, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.